Bank of America Corporation upgraded shares of Teva
Pharmaceutical Industries Limited (NYSE:TEVA) from a neutral rating to a buy
rating in a report released on Tuesday morning.
TEVA has been the topic of a number of other research
reports. Deutsche Bank AG cut their price objective on shares of Teva
Pharmaceutical Industries Limited from $68.00 to $54.00 and set a buy rating on
the stock in a report on Wednesday, November 16th. Morgan Stanley cut shares of
Teva Pharmaceutical Industries Limited from an overweight rating to an equal
weight rating and cut their price objective for the stock from $63.00 to $42.00
in a report on Sunday, December 4th. Jefferies Group LLC reissued a hold rating
and set a $36.00 price objective on shares of Teva Pharmaceutical Industries
Limited in a report on Monday, January 9th. Royal Bank Of Canada cut their target
price on shares of Teva Pharmaceutical Industries Limited from $71.00 to $58.00
and set an outperform rating on the stock in a report on Monday, November 14th.
Finally, BTIG Research cut shares of Teva Pharmaceutical Industries Limited
from a buy rating to a neutral rating in a report on Sunday, December 4th. One
analyst has rated the stock with a sell rating, thirteen have issued a hold
rating, fifteen have assigned a buy rating and one has assigned a strong buy
rating to the company. The stock presently has an average rating of Buy and a
consensus price target of $55.85.
No comments:
Post a Comment